Millennium | Clinicians | Oncology | VELCADE

	MULTIPLE MYELOMA



	MECHANISM
	LANDMARK PHASE 3 APEX TRIAL
	SURVIVAL
	TREATMENT TIMING
	RENAL IMPAIRMENT
	LENGTH OF THERAPY
	RETREATMENT
	SAFETY PROFILE
-	Peripheral Neuropathy
-	Transient Thrombocytopenia
	DOSE MODIFICATION GUIDELINES
	HANDLING AND ADMINISTRATION
	IMPORTANT SAFETY INFORMATION
	REIMBURSEMENT
	ADDITIONAL INFORMATION
	REFERENCES

HANDLING AND ADMINISTRATION GUIDELINES

VELCADE^® (bortezomib) for Injection: How Supplied

	10-mL single-dose vials containing 3.5 mg VELCADE as a lyophilized, white to off-white cake or powder without preservative
	Each single-dose vial is intended for administration to 1 patient
	Unopened vials may be stored at controlled room temperature 25°C/77°F; excursions permitted from 15° to 30°C/59° to 86°F
	Store in original package, protected from light

VELCADE: Reconstitution

Reconstitute with 3.5 mL of normal (0.9%) saline, sodium chloride injection, USP

–	Concentration of reconstituted solution is 1 mg/mL
–	Reconstituted VELCADE should be administered within 8 hours of preparation; this includes time stored in the syringe
–	Reconstituted VELCADE does not need to be protected from indoor light

VELCADE Administration Precautions

	VELCADE is an antineoplastic agent; caution should be used during handling and preparation.
	VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy.
	Proper aseptic technique is essential.
	Use of gloves and other protective clothing is important to prevent contact with skin; VELCADE should be reconstituted under a fume hood.

VELCADE Administration

Direct injection into a peripheral line
Injection into an infusion port

VELCADE is injected by 3-5 second bolus intravenous injection into a peripheral line or into an infusion port.

Normal saline flush should follow injection to ensure full dose.

Infusion reactions and infusion-site reactions are uncommon.

–	In clinical trials, local skin irritation was reported in 5% of patients; no tissue damage was associated with extravasation

Please click here to view additional important safety information.

For full Prescribing Information click here. (pdf) (74KB)

For further information about VELCADE^® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).